{
    "clinical_study": {
        "@rank": "16652", 
        "arm_group": {
            "arm_group_label": "Diagnostic (FDG PET and DCE-MRI)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo FDG PET and DCE-MRI 1-2 weeks prior to chemotherapy initiation, between 1-12 weeks after initiation of the first course of chemotherapy, and after the completion of chemotherapy (within 4 weeks prior to surgery)."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET)\n      and dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in predicting response\n      to treatment in patients with breast cancer. Comparing results of diagnostic procedures done\n      before, during, and after chemotherapy may help doctors predict a patient's response to\n      treatment and help plan the best treatment."
        }, 
        "brief_title": "FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer", 
        "condition": [
            "Male Breast Cancer", 
            "Stage II Breast Cancer", 
            "Stage IIIA Breast Cancer", 
            "Stage IIIB Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Breast Neoplasms, Male"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine whether detailed kinetic analysis of FDG PET and magnetic resonance (MR)\n      imaging studies for measures of tumor metabolism and blood perfusion can predict response\n      and outcome for breast cancer patients undergoing neo-adjuvant therapy.\n\n      II. To compare the in vivo tumor biology associated with responsive and resistant tumors as\n      measured by kinetic changes in FDG PET and MR imaging parameters to tumor subtypes analyzed\n      from assay of pre-therapy biopsy and post-therapy surgical tissue.\n\n      OUTLINE:\n\n      Patients undergo FDG PET and DCE-MRI 1-2 weeks before prior to chemotherapy initiation,\n      between 1-12 weeks after initiation of the first course of chemotherapy, and after the\n      completion of chemotherapy (within 4 weeks prior to surgery)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically confirmed breast cancer, determined to be a candidate for primary\n             systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor\n             following completion of neoadjuvant therapy\n\n          -  Primary tumor 2.0 cm or greater, and/or clinical evidence of axillary disease\n             (palpable N1 or N2 or biopsy proven)\n\n          -  No obvious contraindications for primary chemotherapy\n\n          -  Able to lie still for PET and MRI scanning\n\n          -  Able to understand and willing to sign a written informed consent document and a\n             Health Insurance Portability and Accountability Act (HIPAA) authorization in\n             accordance with institutional guidelines\n\n        Exclusion Criteria:\n\n          -  Serious systemic illness other than breast cancer\n\n          -  Contraindication to MRI or history of adverse reaction to gadolinium\n\n          -  Evidence of distant disease outside of regional lymph nodes\n\n          -  Pregnant\n\n          -  Poorly controlled diabetes mellitus (fasting blood glucose > 200)\n\n          -  Prior systemic cancer therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931709", 
            "org_study_id": "7587", 
            "secondary_id": [
                "NCI-2013-01668", 
                "7587", 
                "P30CA015704", 
                "P50CA138293"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnostic (FDG PET and DCE-MRI)", 
                "description": "Undergo FDG PET", 
                "intervention_name": "fludeoxyglucose F 18", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "18FDG", 
                    "FDG"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (FDG PET and DCE-MRI)", 
                "description": "Undergo FDG PET", 
                "intervention_name": "positron emission tomography", 
                "intervention_type": "Device", 
                "other_name": [
                    "FDG-PET", 
                    "PET", 
                    "PET scan", 
                    "tomography, emission computed"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (FDG PET and DCE-MRI)", 
                "description": "Undergo DCE-MRI", 
                "intervention_name": "dynamic contrast-enhanced magnetic resonance imaging", 
                "intervention_type": "Device", 
                "other_name": "DCE-MRI"
            }, 
            {
                "arm_group_label": "Diagnostic (FDG PET and DCE-MRI)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 13, 2014", 
        "location": {
            "contact": {
                "last_name": "Jennifer M. Specht", 
                "phone": "206-288-6889"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
            }, 
            "investigator": {
                "last_name": "Jennifer M. Specht", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Quantitative Dynamic PET and MRI and Breast Cancer Therapy", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", 
            "last_name": "Jennifer Specht", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary clinical endpoint is dichotomous (yes/no). Associations with pathologic response will be estimated using logistic regression.", 
            "measure": "Microscopic pathologic response, defined as no evidence of microscopic invasive tumor present at primary tumor site in the surgical specimen, as opposed to results \"other than pathologic complete response (pCR)\"", 
            "safety_issue": "No", 
            "time_frame": "At time of surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931709"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Relationships between imaging variables and gene expression measured at pre-therapy will be examined by linear regression models.", 
                "measure": "Percent change in tumor perfusion", 
                "safety_issue": "No", 
                "time_frame": "Baseline to up to 12 weeks (mid-therapy)"
            }, 
            {
                "description": "Relationships between imaging variables and gene expression measured at pre-therapy will be examined by linear regression models.", 
                "measure": "Percent change in tumor metabolism", 
                "safety_issue": "No", 
                "time_frame": "Baseline to up to 12 weeks (mid-therapy)"
            }, 
            {
                "description": "Will be examined using Cox proportional hazards regression.", 
                "measure": "Time from surgery to breast cancer recurrence or death", 
                "safety_issue": "No", 
                "time_frame": "From surgery to breast cancer recurrence or death, assessed up to 5 years"
            }, 
            {
                "description": "Will be examined using Cox proportional hazards regression.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From time of surgery until death, assessed up to 5 years"
            }
        ], 
        "source": "University of Washington", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Washington", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}